Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Miller M, Ballantyne C, Bays H, Granowitz C, Doyle R, Juliano R, Philip S. Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces potentially atherogenic lipid, lipoprotein, apolipoprotein, and inflammatory parameters in high-risk, statin-treated patients with persistent elevated triglycerides and high-sensitivity C-reactive protein: a post hoc subanalysis of the ANCHOR study [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1392. http://www.onlinejacc.org/content/71/11_Supplement/A1392

Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT Jr, Juliano RA, Philip S. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study). Am J Cardiol.2019; epub ahead of print.
https://www.ajconline.org/article/S0002-9149(19)30637-X/pdf
https://www.ncbi.nlm.nih.gov/pubmed/31277790

https://www.ncbi.nlm.nih.gov/pubmed/31277790
Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides
Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides [abstract]. Circulation. 2017;136(suppl 1):A15097.

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA. Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials). Am J Cardiol. 2017; 119:397-403.
Free:

http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf
Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome.
Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome. Metab Syndr Relat Disord. 2015;13:239-247.
Free:
http://online.liebertpub.com/doi/pdfplus/10.1089/met.2014.0137
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
Free:
http://www.cardiab.com/content/pdf/1475-2840-12-100.pdf
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies
Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13:37-46.
Free:
http://link.springer.com/article/10.1007/s40256-012-0002-3
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565-572.
https://www.lipidjournal.com/article/S1933-2874(12)00273-5/fulltext
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984-992.
Free:
https://www.ajconline.org/article/S0002-9149(12)01432-4/pdf

Vijay K, Szerlip HM, Ballantyne CM, Nelson JR, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and elevated high-sensitivity C-reactive protein =2.0 mg/L [abstract 317]. Am J Kidney Dis. 2018;71(4):594-595.

http://www.ajkd.org/article/S0272-6386(18)30454-2/fulltext

Amarin Corporation